Bristol-Myers Squibb, Celgene likely to face longer US antitrust probe
Bristol-Myers Squibb’s plan to buy Celgene likely faces an extended US antitrust investigation, given the impact of the partial federal government shutdown and size of the deal. But a longer review...To view the full article, register now.
Already a subscriber? Click here to view full article